Nabriva Therapeutics AG (NASDAQ:NBRV)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Friday, May 12th.
Several other research firms have also recently commented on NBRV. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, March 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a research report on Tuesday, April 11th. Zacks Investment Research cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research report on Thursday, January 26th. Finally, Wedbush reissued an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a research report on Tuesday, January 31st. Seven research analysts have rated the stock with a buy rating, Nabriva Therapeutics AG currently has an average rating of “Buy” and an average target price of $15.29.
Nabriva Therapeutics AG (NBRV) traded up 2.91% during midday trading on Friday, hitting $9.20. The stock had a trading volume of 15,843 shares. The company’s market cap is $250.33 million. The company’s 50 day moving average is $9.92 and its 200 day moving average is $9.14. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75.
In other news, Director George Harrison Talbot sold 325 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total value of $32,682.00. Following the transaction, the director now owns 3,854 shares of the company’s stock, valued at $387,558.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 90,594 shares of the business’s stock in a transaction on Monday, April 10th. The stock was sold at an average price of $10.96, for a total transaction of $992,910.24. Following the completion of the transaction, the insider now directly owns 269,371 shares in the company, valued at approximately $2,952,306.16. The disclosure for this sale can be found here. Insiders have sold 166,703 shares of company stock worth $1,911,919 in the last ninety days.
Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new stake in Nabriva Therapeutics AG during the first quarter worth about $139,000. Renaissance Technologies LLC acquired a new stake in Nabriva Therapeutics AG during the fourth quarter worth about $103,000. FT Options LLC increased its stake in Nabriva Therapeutics AG by 43.1% in the fourth quarter. FT Options LLC now owns 83,055 shares of the biotechnology company’s stock worth $494,000 after buying an additional 25,000 shares during the last quarter. Almanack Investment Partners LLC. acquired a new stake in Nabriva Therapeutics AG during the first quarter worth about $1,870,000. Finally, Nationwide Fund Advisors acquired a new stake in Nabriva Therapeutics AG during the first quarter worth about $2,074,000. 55.90% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.